{"id":12993,"date":"2025-03-06T10:14:48","date_gmt":"2025-03-06T10:14:48","guid":{"rendered":"https:\/\/www.mapcommunication.it\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/"},"modified":"2026-02-24T11:32:46","modified_gmt":"2026-02-24T11:32:46","slug":"cystic-fibrosis-a-major-step-forward-for-patients","status":"publish","type":"blog-post","link":"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/","title":{"rendered":"CYSTIC FIBROSIS: A MAJOR STEP FORWARD FOR PATIENTS"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\" id=\"h-parere-favorevole-del-chmp-per-estendere-l-indicazione-terapeutica-dei-due-medicinali-kaftrio-e-kalydeco\">CHMP favourable opinion to extend the therapeutic indication of the two medicinal products Kaftrio and Kalydeco<\/h3>\n\n<p class=\"wp-block-paragraph\">Very important news has come from the <strong>Committee for Medicinal Products for Human Use<\/strong> (CHMP) of the <strong>EMA<\/strong> (European Medicines Agency) for the future of many people affected by <strong>Cystic Fibrosis<\/strong>: the agency has in fact recommended extending the <strong>therapeutic indication<\/strong> of two medicines, Kaftrio (ivacaftor-tezacaftor-elexacaftor) and Kalydeco (ivacaftor), for the treatment of the disease, including their use in combination for patients aged two years and older who have at least one non-class I mutation (stop mutations) in the CFTR (cystic fibrosis transmembrane conductance regulator) gene. The extension of the indication will make it possible to treat all patients who may benefit from these therapies, meaning that approximately 95-97% of patients with cystic fibrosis in the European Union (EU) could benefit. This represents an increase of 15-17% over the previous indication.  <\/p>\n\n<p class=\"wp-block-paragraph\">The CHMP recommendation is based on the evaluation of efficacy and safety data from clinical and in vitro (laboratory) studies, including a randomised placebo-controlled study, an open-arm study, data from a real evidence study conducted by the Cystic Fibrosis Foundation of the United States, as well as literature data obtained through a compassionate use programme in France.<\/p>\n<div class=\"wp-block-image\">\n<figure class=\"w-richtext-figure-type-image w-richtext-align-fullwidth alignleft size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"421\" height=\"633\" src=\"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/03\/Antonio-Guarini_presidente-LIFC-Lega-Italiana-Fibrosi-Cistica-ODV.png\" alt=\"\" class=\"wp-image-13505\" srcset=\"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/03\/Antonio-Guarini_presidente-LIFC-Lega-Italiana-Fibrosi-Cistica-ODV.png 421w, https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/03\/Antonio-Guarini_presidente-LIFC-Lega-Italiana-Fibrosi-Cistica-ODV-200x300.png 200w\" sizes=\"auto, (max-width: 421px) 100vw, 421px\" \/><\/figure>\n<\/div>\n<p class=\"wp-block-paragraph\">\u201c<em>This opinion is a very important step<\/em> \u2013 states Antonio Guarini, <strong>President of the Italian<\/strong> <strong>Cystic Fibrosis League ODV <\/strong>\u2013 <em>As a leading association for patients and families in Italy, we have been following this process for some time: we will continue our commitment at the national level to ensure that more and more patients can access care that improves their quality of life\u201d.<\/em><\/p>\n\n<p class=\"wp-block-paragraph\">The favourable CHMP opinion represents an intermediate step for patient <strong>access to Kaftrio and Kalydeco<\/strong>. The next step is now awaited, which will decide on the extension of the therapeutic indication to the European level. Once the extension has been granted, price and reimbursement decisions will be taken at the level of each Member State, taking into account the possible role and use of these drugs in the context of their national health systems.  <\/p>\n\n<p class=\"wp-block-paragraph\"><em>The full text is public on the EMA website: <a href=\"https:\/\/www.ema.europa.eu\/en\/news\/combination-cystic-fibrosis-medicines-treat-patients-rare-mutations\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.ema.europa.eu\/en\/news\/combination-cystic-fibrosis-medicines-treat-patients-rare-mutations<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CHMP favourable opinion to extend the therapeutic indication of the two medicinal products Kaftrio and Kalydeco Very important news has come from the Committee for Medicinal Products for Human Use (CHMP) of the EMA (European Medicines Agency) for the future of many people affected by Cystic Fibrosis: the agency has in fact recommended extending the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":12992,"template":"","class_list":["post-12993","blog-post","type-blog-post","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.5 (Yoast SEO v26.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CYSTIC FIBROSIS: A MAJOR STEP FORWARD FOR PATIENTS - Agenzia di Comunicazione e Marketing Integrato<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CYSTIC FIBROSIS: A MAJOR STEP FORWARD FOR PATIENTS\" \/>\n<meta property=\"og:description\" content=\"CHMP favourable opinion to extend the therapeutic indication of the two medicinal products Kaftrio and Kalydeco Very important news has come from the Committee for Medicinal Products for Human Use (CHMP) of the EMA (European Medicines Agency) for the future of many people affected by Cystic Fibrosis: the agency has in fact recommended extending the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Agenzia di Comunicazione e Marketing Integrato\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/mapcommunication.agency\/#\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T11:32:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/11\/fibrosi-cistica_map_news_EMA_CHMP_farmaci-821x1024-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"821\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/\",\"url\":\"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/\",\"name\":\"CYSTIC FIBROSIS: A MAJOR STEP FORWARD FOR PATIENTS - Agenzia di Comunicazione e Marketing Integrato\",\"isPartOf\":{\"@id\":\"https:\/\/www.mapcommunication.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/11\/fibrosi-cistica_map_news_EMA_CHMP_farmaci-821x1024-1.jpg\",\"datePublished\":\"2025-03-06T10:14:48+00:00\",\"dateModified\":\"2026-02-24T11:32:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/#primaryimage\",\"url\":\"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/11\/fibrosi-cistica_map_news_EMA_CHMP_farmaci-821x1024-1.jpg\",\"contentUrl\":\"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/11\/fibrosi-cistica_map_news_EMA_CHMP_farmaci-821x1024-1.jpg\",\"width\":821,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mapcommunication.it\/en\/map-communication\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Blog Posts\",\"item\":\"https:\/\/www.mapcommunication.it\/en\/blog-post\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CYSTIC FIBROSIS: A MAJOR STEP FORWARD FOR PATIENTS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mapcommunication.it\/en\/#website\",\"url\":\"https:\/\/www.mapcommunication.it\/en\/\",\"name\":\"MAP Communication\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mapcommunication.it\/en\/#organization\"},\"alternateName\":\"Agenzia di Comunicazione e Marketing Integrato | Map Communication\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mapcommunication.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mapcommunication.it\/en\/#organization\",\"name\":\"MAP Communication\",\"url\":\"https:\/\/www.mapcommunication.it\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.mapcommunication.it\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/11\/Logo-MAP.png\",\"contentUrl\":\"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/11\/Logo-MAP.png\",\"width\":591,\"height\":214,\"caption\":\"MAP Communication\"},\"image\":{\"@id\":\"https:\/\/www.mapcommunication.it\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/mapcommunication.agency\/#\",\"https:\/\/www.instagram.com\/mapcommunication\",\"https:\/\/www.linkedin.com\/company\/map-communication\/posts\/?feedView=all\",\"https:\/\/www.youtube.com\/MapPublicRelations\"],\"description\":\"MAP Communication is a strategic communication agency founded in 1979.\",\"email\":\"info@mapcommunication.it\",\"telephone\":\"+39 0733.672042\",\"legalName\":\"MAP srl\",\"vatID\":\"00910850437\",\"foundingDate\":\"1979\",\"address\":{\"@type\":\"PostalAddress\",\"streetAddress\":\"Via Cesare Battisti, 44\",\"addressLocality\":\"Potenza Picena\",\"addressRegion\":\"MC\",\"postalCode\":\"62018\",\"addressCountry\":\"IT\"},\"contactPoint\":[{\"@type\":\"ContactPoint\",\"telephone\":\"+39-0733-672042\",\"contactType\":\"customer service\",\"areaServed\":[\"IT\",\"US\",\"GB\"],\"availableLanguage\":[\"Italian\",\"English\"]},{\"@type\":\"ContactPoint\",\"telephone\":\"+39-320-3684559\",\"contactType\":\"customer service\",\"description\":\"Mobile\"}],\"location\":[{\"@type\":\"Place\",\"name\":\"Sede Legale e Operativa - Potenza Picena\",\"address\":{\"@type\":\"PostalAddress\",\"streetAddress\":\"Via Cesare Battisti, 44\",\"addressLocality\":\"Potenza Picena\",\"addressRegion\":\"MC\",\"postalCode\":\"62018\",\"addressCountry\":\"IT\"},\"geo\":{\"@type\":\"GeoCoordinates\",\"latitude\":\"43.3644\",\"longitude\":\"13.6219\"}},{\"@type\":\"Place\",\"name\":\"Sede Operativa - Milano\",\"address\":{\"@type\":\"PostalAddress\",\"streetAddress\":\"Via Carlo Giuseppe Merlo, 1\",\"addressLocality\":\"Milano\",\"addressRegion\":\"MI\",\"postalCode\":\"20122\",\"addressCountry\":\"IT\"}}],\"founder\":[{\"@type\":\"Person\",\"name\":\"Mario Carlocchia\",\"jobTitle\":\"Founder\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/mario-carlocchia-a5431b23\/\"]},{\"@type\":\"Person\",\"name\":\"Antonella Mazzarella\",\"jobTitle\":\"Founder\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/antonella-mazzarella-02753a106\/\"]}]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CYSTIC FIBROSIS: A MAJOR STEP FORWARD FOR PATIENTS - Agenzia di Comunicazione e Marketing Integrato","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/","og_locale":"en_US","og_type":"article","og_title":"CYSTIC FIBROSIS: A MAJOR STEP FORWARD FOR PATIENTS","og_description":"CHMP favourable opinion to extend the therapeutic indication of the two medicinal products Kaftrio and Kalydeco Very important news has come from the Committee for Medicinal Products for Human Use (CHMP) of the EMA (European Medicines Agency) for the future of many people affected by Cystic Fibrosis: the agency has in fact recommended extending the [&hellip;]","og_url":"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/","og_site_name":"Agenzia di Comunicazione e Marketing Integrato","article_publisher":"https:\/\/www.facebook.com\/mapcommunication.agency\/#","article_modified_time":"2026-02-24T11:32:46+00:00","og_image":[{"width":821,"height":1024,"url":"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/11\/fibrosi-cistica_map_news_EMA_CHMP_farmaci-821x1024-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/","url":"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/","name":"CYSTIC FIBROSIS: A MAJOR STEP FORWARD FOR PATIENTS - Agenzia di Comunicazione e Marketing Integrato","isPartOf":{"@id":"https:\/\/www.mapcommunication.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/11\/fibrosi-cistica_map_news_EMA_CHMP_farmaci-821x1024-1.jpg","datePublished":"2025-03-06T10:14:48+00:00","dateModified":"2026-02-24T11:32:46+00:00","breadcrumb":{"@id":"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/#primaryimage","url":"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/11\/fibrosi-cistica_map_news_EMA_CHMP_farmaci-821x1024-1.jpg","contentUrl":"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/11\/fibrosi-cistica_map_news_EMA_CHMP_farmaci-821x1024-1.jpg","width":821,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/www.mapcommunication.it\/en\/news\/cystic-fibrosis-a-major-step-forward-for-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mapcommunication.it\/en\/map-communication\/"},{"@type":"ListItem","position":2,"name":"Blog Posts","item":"https:\/\/www.mapcommunication.it\/en\/blog-post\/"},{"@type":"ListItem","position":3,"name":"CYSTIC FIBROSIS: A MAJOR STEP FORWARD FOR PATIENTS"}]},{"@type":"WebSite","@id":"https:\/\/www.mapcommunication.it\/en\/#website","url":"https:\/\/www.mapcommunication.it\/en\/","name":"MAP Communication","description":"","publisher":{"@id":"https:\/\/www.mapcommunication.it\/en\/#organization"},"alternateName":"Agenzia di Comunicazione e Marketing Integrato | Map Communication","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mapcommunication.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.mapcommunication.it\/en\/#organization","name":"MAP Communication","url":"https:\/\/www.mapcommunication.it\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.mapcommunication.it\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/11\/Logo-MAP.png","contentUrl":"https:\/\/www.mapcommunication.it\/wp-content\/uploads\/2025\/11\/Logo-MAP.png","width":591,"height":214,"caption":"MAP Communication"},"image":{"@id":"https:\/\/www.mapcommunication.it\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/mapcommunication.agency\/#","https:\/\/www.instagram.com\/mapcommunication","https:\/\/www.linkedin.com\/company\/map-communication\/posts\/?feedView=all","https:\/\/www.youtube.com\/MapPublicRelations"],"description":"MAP Communication is a strategic communication agency founded in 1979.","email":"info@mapcommunication.it","telephone":"+39 0733.672042","legalName":"MAP srl","vatID":"00910850437","foundingDate":"1979","address":{"@type":"PostalAddress","streetAddress":"Via Cesare Battisti, 44","addressLocality":"Potenza Picena","addressRegion":"MC","postalCode":"62018","addressCountry":"IT"},"contactPoint":[{"@type":"ContactPoint","telephone":"+39-0733-672042","contactType":"customer service","areaServed":["IT","US","GB"],"availableLanguage":["Italian","English"]},{"@type":"ContactPoint","telephone":"+39-320-3684559","contactType":"customer service","description":"Mobile"}],"location":[{"@type":"Place","name":"Sede Legale e Operativa - Potenza Picena","address":{"@type":"PostalAddress","streetAddress":"Via Cesare Battisti, 44","addressLocality":"Potenza Picena","addressRegion":"MC","postalCode":"62018","addressCountry":"IT"},"geo":{"@type":"GeoCoordinates","latitude":"43.3644","longitude":"13.6219"}},{"@type":"Place","name":"Sede Operativa - Milano","address":{"@type":"PostalAddress","streetAddress":"Via Carlo Giuseppe Merlo, 1","addressLocality":"Milano","addressRegion":"MI","postalCode":"20122","addressCountry":"IT"}}],"founder":[{"@type":"Person","name":"Mario Carlocchia","jobTitle":"Founder","sameAs":["https:\/\/www.linkedin.com\/in\/mario-carlocchia-a5431b23\/"]},{"@type":"Person","name":"Antonella Mazzarella","jobTitle":"Founder","sameAs":["https:\/\/www.linkedin.com\/in\/antonella-mazzarella-02753a106\/"]}]}]}},"_links":{"self":[{"href":"https:\/\/www.mapcommunication.it\/en\/wp-json\/wp\/v2\/post-type\/blog-post\/12993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mapcommunication.it\/en\/wp-json\/wp\/v2\/post-type\/blog-post"}],"about":[{"href":"https:\/\/www.mapcommunication.it\/en\/wp-json\/wp\/v2\/types\/blog-post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mapcommunication.it\/en\/wp-json\/wp\/v2\/users\/2"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mapcommunication.it\/en\/wp-json\/wp\/v2\/media\/12992"}],"wp:attachment":[{"href":"https:\/\/www.mapcommunication.it\/en\/wp-json\/wp\/v2\/media?parent=12993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}